Merck & Co. has filed suit to stop Novartis AG’s Sandoz division from selling a generic version of its antifungal drug Cancidas. Filing the patent infringement lawsuit will keep the Food and Drug Administration from approving Sandoz’s generic for 30 months, or until the litigation is resolved. Merck said Sandoz is challenging a formulation patent that is set to expire in 2017.
Merck filed suit against another generic drugmaker, Teva Pharmaceutical Industries Ltd., in November over the same drug. Cancidas was approved in January 2001 as a treatment for fungal infections. According to Merck, U.S. sales totaled $73 million in 2009. Merck said it hopes to resolve the lawsuits before the mandatory waiting periods are over. The waiting period for Teva ends on April 22, 2012, and on August 25, 2012 for Sandoz.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.